Financial Performance - U.S product revenue increased to $43 million in Q4 2020, a 38% year-over-year growth, and reached $141 million for the full year 2020, a 30% increase compared to 2019[35] - Total revenue reached $44 million in Q4 2020, a 36% year-over-year growth, and $145 million for the full year 2020, a 28% increase compared to 2019[35] - Non-GAAP gross margin was 76% in Q4 2020 and 77% for the full year 2020[36] - R&D expenses increased to $47 million in Q4 2020, a 46% year-over-year growth, and reached $166 million for the full year 2020, a 30% increase compared to 2019[38] - Strategic channel drives 95% of sales[31] Growth Drivers and Initiatives - New product revenue contribution reached 75% in Q4 2020[6, 14] - Average revenue per case grew by 13% year-over-year[6, 24] - Revenue per surgeon increased by 15% year-over-year[6, 24] - The company is advancing towards exclusive U S distribution[11] Future Outlook - U S revenue for FY 2021 is projected to be approximately $176 million, representing a 25% year-over-year growth[41] - Total revenue for FY 2021 is expected to be around $178 million, a 23% increase year-over-year[41]